Advertisement

Topics

MK3207 for Treatment of Acute Migraines

2014-07-23 21:21:52 | BioPortfolio

Summary

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Migraine

Intervention

MK3207, Comparator: placebo (unspecified)

Status

Completed

Source

Merck

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:21:52-0400

Clinical Trials [883 Associated Clinical Trials listed on BioPortfolio]

A Study of Gastric Delay in Migraine Patients

A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.

Sitagliptin vs Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency

The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in patients with moderate and severe renal insufficiency.

MK0974 Pivotal Study 1 - WW (With Active Comparator)

The purpose of this study is to investigate the efficacy and safety of MK0974 compared to an approved medication for acute migraine.

A Study to Test the Safety and Effectiveness of MK0974 Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura.

This study will test the safety and how effective MK0974 is when taken with Ibuprofen or Acetaminophen in patients with migraine with or without aura.

Safety and Efficacy Study of MK0974 in the Acute Migraine

The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.

PubMed Articles [1086 Associated PubMed Articles listed on BioPortfolio]

The Migraine Postdrome.

The migraine postdrome is the least studied and least understood phase of migraine. This article covers the salient features of the migraine postdrome and provides insight into the history, clinical s...

Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application.

Migraine is a neurological disease characterized by recurring attacks that can cause severe disabling pain. This study described the burden of migraine as reported by individuals with migraine in the ...

White matter tract microstructure of the mPFC-amygdala predicts interindividual differences in placebo response related to treatment in migraine patients.

To investigate whether interindividual variability of white matter (WM) tract microstructure of the medial prefrontal cortex (mPFC)-amygdala circuit could predict 8-week placebo treatment outcomes in ...

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.

To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment.

Headache: Migraine.

Migraine is a primary headache disorder and a common, recurrent, disabling condition that affects an estimated 18% of women and 6% of men. Commonly reported triggers that induce migraine include stres...

Medical and Biotech [MESH] Definitions

A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

Serotonin antagonist used against MIGRAINE DISORDERS and vascular headaches.

More From BioPortfolio on "MK3207 for Treatment of Acute Migraines"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial